2021 GBT440-032 “HOPE Kids 2” – A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of Voxelotor (GBT440) in Paediatric Participants with Sickle Cell Disease and an Open-label Study in Infants with Sickle Cell Disease
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros.
Previous Post2020 IMR-SCD-301 ‘IMARA’ – A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease
Next Post2022 GBT440-042 – Phase 3, Multicenter, Randomized, Double-Blind, PlaceboControlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell Disease
